Gene Therapy and Vaccines Faculty
All CAMB Faculty | CB Faculty | CPM Faculty | DSRB Faculty | G&E Faculty | GTV Faculty | MVP Faculty
Current Members
Gene Therapy and Vaccines
Click the faculty member's name to see more detailed information.
Faculty
Faculty areas of research in GTV can be broken up into the following categories:
- Autoimmunity
- Cancer
- Cardiovascular Disease
- Ex vivo Gene Therapy
- Gene Editing
- Gene Therapy
- Immune Therapy
- Neurodegenerative Disease
- Vaccine Development
| Faculty name | Brief Research Description |
|---|---|
| Henry Daniell | Autoimmunity, Drug Delivery |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Laura Su | We are interested in how previous antigen experiences impact T cell resposnes to vaccines, infections, and the risk for autoimmunity |
| Faculty name | Brief Research Description |
|---|---|
| Steven Albelda | Solid Tumors |
| Gregory Beatty | Solid Tumors |
| Frederic Bushman | Human microbiome, human gene therapy HIV, Poxviruses, DNA modifying enzymes, Lateral DNA transfer |
| Hildegund Ertl | Our vaccine efforts focus on the development of viral vector based vaccines to cancer and chronic and emerging viral infections. Our gene therapy efforts focus on pathways to prevent immune-mediated rejection of AAV vectors targeted to liver |
| Peter Kurre | AML, crosstalk in the microenvironment, extracellular vesicles |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Nicola Mason | Solid Tumors |
| Hamideh Parhiz | mRNA therapeutics, nucleic acid therapeutics, targeted therapeutics, gene therapy, nanomedicine |
| Avery Posey | We are fascinated with the study of sugars (glycans) within cancer immunology. We identify novel differentially glycosylated peptides on tumor cells and design chimeric antigen receptors to target these antigens. Additionally, we alter the glycome of immune cells and study their roles in effector immune functions. |
| Daniel Powell | Solid tumors |
| Andrew Tsourkas | Targeted therapeutics, nanomedicine, protein engineering, bioconjugate chemistry, antibody therapeutics, molecular imaging |
| Evan Weber | CAR-T, exhaustion, epigenome engineering, CRISPR |
| David Weiner |
Invivo genetic delivery, Nucleic Acid delivery, DNA vaccines, Biologics, T cell responses |
| Faculty name | Brief Research Description |
|---|---|
| Kiran Musunuru | Atherosclerosis, Cardiovascular Disease, Gene Editing, Lipid Metabolism |
| Daniel Rader | Atherosclerosis, Cardiovascular Disease, Lipid Metabolism, Human Genetics, Functional Genomics |
| Faculty name | Brief Research Description |
|---|---|
| Frederic Bushman | Human microbiome, human gene therapy HIV, Poxviruses, DNA modifying enzymes, Lateral DNA transfer |
| Peter Kurre | Bone Marrow Failure, Congenital dyserythropoietic anemia, Congenital Sideroblastic Anemia, DBA, Extracellular Vesicle Biology, Fanconi Anemia, HSCs, Lentiviral Vectors |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Hamideh Parhiz | mRNA therapeutics, nucleic acid therapeutics, targeted therapeutics, gene therapy, nanomedicine |
| Daniel Powell | Engineered CAR T cells and tumor infiltrating lymphocytes |
| Stefano Rivella | The focus of the Rivella lab is to gene transfer and genome editing, using hematopoietic stem cells (HSC) as a target. We are also developing new approaches to target HSC in vivo. |
| John Wolfe | Rare disease, Metabolic disease, Genetic disease, Mechanism pathology, Brain, CNS, AAV, Neuroimaging |
| Faculty name | Brief Research Description |
|---|---|
| Frederic Bushman | Human microbiome, human gene therapy HIV, Poxviruses, DNA modifying enzymes, Lateral DNA transfer |
| Beverly Davidson | AAV Vectors, Gene Editing, Neurodegenerative Disease |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Kiran Musunuru | Atherosclerosis, Cardiovascular Disease, Gene Editing, Lipid Metabolism |
| Hamideh Parhiz | mRNA therapeutics, nucleic acid therapeutics, targeted therapeutics, gene therapy, nanomedicine |
| Daniel Powell | CRISPR based gene insertion/deletion |
| Stefano Rivella | The focus of the Rivella lab is to gene transfer and genome editing, using hematopoietic stem cells (HSC) as a target. We are also developing new approaches to target HSC in vivo. |
| Evan Weber | CAR-T, exhaustion, epigenome engineering, CRISPR |
| Faculty name | Brief Research Description |
|---|---|
| Jean Bennett | Eye Disease, Neurodegenerative Disease |
| Frederic Bushman | Human microbiome, human gene therapy HIV, Poxviruses, DNA modifying enzymes, Lateral DNA transfer |
| Beverly Davidson | AAV Vectors, Gene Editing, Neurodegenerative Disease |
| Hildegund Ertl | Our vaccine efforts focus on the development of viral vector based vaccines to cancer and chronic and emerging viral infections. Our gene therapy efforts focus on pathways to prevent immune-mediated rejection of AAV vectors targeted to liver |
| Peter Kurre | Hematopoietic Stem Cell Gene Therapy, bone marrow failure, mRNA therapeutics |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Hamideh Parhiz | mRNA therapeutics, nucleic acid therapeutics, targeted therapeutics, gene therapy, nanomedicine |
| Daniel Rader | Atherosclerosis, Cardiovascular Disease, Lipid Metabolism, Human Genetics, Functional Genomics |
| Stefano Rivella | The focus of the Rivella lab is to gene transfer and genome editing, using hematopoietic stem cells (HSC) as a target. We are also developing new approaches to target HSC in vivo. |
| Denise Sabatino | The lab focuses on development of novel factor VIII proteins with enhanced function, AAV-mediated gene therapy for hemophilia and understanding the biological consequences of AAV delivery of factor VIII. |
| Benjamin Samelson-Jones | AAV vectors, hemophilia, coagulation biochemistry |
| Dwight Stambolian | Eye Disease |
| Hansell Stedman | AAV Vectors, Muscular Dystrophy, Gene Therapy |
| Katherine Uyhazi | Retinal gene therapy, vision science, photoreceptor regeneration, ophthalmology |
| James Wilson | AAV Vectors, Adenoviruses, Gene editing, COVID19 |
| John Wolfe | Rare disease, Metabolic disease, Genetic disease, Mechanism pathology, Brain, CNS, AAV, Neuroimaging |
| Faculty name | Brief Research Description |
|---|---|
| Frederic Bushman | Human microbiome, human gene therapy HIV, Poxviruses, DNA modifying enzymes, Lateral DNA transfer |
| Bruce Freedman | Immune Therapies |
| Saar Gill | Adoptive Cellular Therapy, CART, HSCs, Immune Therapy, Liquid Tumors |
| Stephen Grupp | Adoptive Cellular Therapy, CART, Immune Therapy, Liquid Tumors |
| Carl June | Adoptive Cellular Therapy, CART, Immune Therapy, Liquid Tumors |
| Daniel Kulp | DNA vaccine, immune therapy, protein engineering |
| Bruce Levine | Adoptive Cellular Therapy, CART, Immune Therapy, Liquid Tumors |
| Gerald Linette | Human Cancer Immunology is the focus of our laboratory. We isolate TCRs specific for neoantigen p-MHC expressed in solid tumors. Emphasis is placed on translation to the clinic. |
| Michela Locci | Complex biology of Tfh cells using a multidisciplinary approach that combines cellular and molecular immunology as well as transcriptomics. T follicular helper and antibody responses following immunization with SARS-CoV-2 mRNA vaccines |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Nicola Mason | Solid Tumors |
| Michael Milone | Adoptive Cellular Therapy, CART, Immune Therapy, Liquid Tumors |
| Hamideh Parhiz | mRNA therapeutics, nucleic acid therapeutics, targeted therapeutics, gene therapy, nanomedicine |
| Avery Posey | We are fascinated with the study of sugars (glycans) within cancer immunology. We identify novel differentially glycosylated peptides on tumor cells and design chimeric antigen receptors to target these antigens. Additionally, we alter the glycome of immune cells and study their roles in effector immune functions. |
| Daniel Powell | Immune checkpoint inhibitors, cytokines, vaccines, TIL immunobiology and therapy |
| Marco Ruella | The lab focuses on development of novel factor VIII proteins with enhanced function, AAV-mediated gene therapy for hemophilia and understanding the biological consequences of AAV delivery of factor VIII. |
| Andrew Tsourkas | Targeted therapeutics, nanomedicine, protein engineering, bioconjugate chemistry, antibody therapeutics, molecular imaging |
| Evan Weber | CAR-T, exhaustion, epigenome engineering, CRISPR |
| David Weiner |
Invivo genetic delivery, Nucleic Acid delivery, DNA vaccines, Biologics, T cell responses |
| Faculty name | Brief Research Description |
|---|---|
| Frederick (Chris) Bennett | Neurodegenerative diseases, Microglia |
| Beverly Davidson | AAV Vectors, Gene Editing, Neurodegenerative Disease |
| Stephen Douglas | Neurodegenerative Disease |
| Daniel Rader | Alzheimer’s disease, lipids, genetics |
| Stefano Rivella | The focus of the Rivella lab is to gene transfer and genome editing, using hematopoietic stem cells (HSC) as a target. We are also developing new approaches to target HSC in vivo. |
| Dwight Stambolian | Single cell biology, Age-related macular degeneration, retina, RPE-choroid, Alzheimer’s Disease |
| Katherine Uyhazi | Retinal gene therapy, vision science, photoreceptor regeneration, ophthalmology |
| Adeline Vanderver | Neurogenetic disorders and therapeutics |
| John Wolfe | Rare disease, Metabolic disease, Genetic disease, Mechanism pathology, Brain, CNS, AAV, Neuroimaging |
| Faculty name | Brief Research Description |
|---|---|
| Beatriz Carreno | Solid Tumors, Vaccine |
| Hildegund Ertl | Our vaccine efforts focus on the development of viral vector based vaccines to cancer and chronic and emerging viral infections. Our gene therapy efforts focus on pathways to prevent immune-mediated rejection of AAV vectors targeted to liver |
| Michela Locci | Vaccine durability, immune responses, neutralizing antibodies, T follicular helper cells, memory B cells |
| Leyuan Ma | Immune Engineering, ImmunoModulation, ImmunoSensing, ImmunoTherapy |
| Luis Montaner | HIV, Vaccine, COVID19 |
| Paul Offit |
Vaccine |
| Norbert Pardi | RNA Delivery, Vaccine |
| Laura Su | We are interested in how previous antigen experiences impact T cell resposnes to vaccines, infections, and the risk for autoimmunity |
| David Weiner |
Invivo genetic delivery, Nucleic Acid delivery, DNA vaccines, Biologics, T cell responses |
For information on how to apply for CAMB Faculty membership, please see the CAMB Bylaws.